2C-P
2C-P (2,5-dimethoxy-4-propylphenethylamine) is one of the most potent and longest-lasting members of the 2C phenethylamine series. Active doses are small and the margin between a strong experience and an overwhelming one is narrow, making accurate dosing especially difficult. Effects can last 10-16 hours. There are no controlled human studies; all information is anecdotal or drawn from PiHKAL.
01 Overview
2C-P is a 5-HT2A receptor agonist notable for both its high potency and its unusually long duration among the 2C compounds. Because active oral doses are in the single-digit to low double-digit milligram range, small weighing errors translate into large differences in effect, and delayed onset frequently leads people to redose before the first dose has taken hold.
Reports describe intense, immersive visual and cognitive effects that build slowly over several hours and persist well into the following day. The combination of potency, slow onset and long duration makes 2C-P one of the more hazardous 2C compounds to dose. Human pharmacology and toxicology remain essentially uncharacterised.
02 Mechanism
Potent agonist at serotonin 5-HT2A receptors; the propyl substitution greatly increases potency relative to shorter-chain 2C analogues.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Threshold | 3–5 mg | Oral | Onset can be delayed several hours; do not redose early. |
| Common | 6–10 mg | Oral | Narrow margin; small increases sharply raise intensity and duration. |
| Strong | 10–16 mg | Oral | High risk of an overwhelming, very long experience. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Intense visual geometryComplex, immersive open- and closed-eye visuals reported at common and strong doses. | strong | Anecdotal | |
| Very long durationEffects build slowly and persist far longer than most 2C compounds. | 10-16 h | Anecdotal | |
| Cognitive and emotional intensityStrong introspective and thought-altering effects. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Nausea and body loadGastrointestinal discomfort during the long onset phase. | Mild | Common | Anecdotal | |
| Anxiety and panicIntense, long-lasting effects can precipitate acute anxiety. | Moderate | Common | Anecdotal | |
| Overwhelming experience from redosingSlow onset leads users to take more before the first dose peaks, producing dangerously intense, prolonged states. | Severe | Common | Anecdotal |